Signal Management
Including signal detection, validation, prioritization, and assessment
Signal Management Services
ProPharma has deep expertise across all signal detection and management activities, including validation, prioritization, and assessment using data from a wide range of sources that are relevant for signal detection for the individual product(s). We are also fully trained and experienced in the EudraVigilance Data Analysis System (EVDAS) functionality and can support MAHs to comply with their obligations for signal detection and management. We leverage our robust knowledge to select the most efficient and effective method(s) for each product that is compliant with legislative requirements.
ProPharma's simple but scalable model of signal detection and management allows clients to obtain the exact services necessary throughout the entire life cycle of their products.
Signal management is a critical process for the proactive and timely identification of potential new safety risks for medicinal products that require the utmost expertise. Signal management can be deployed throughout both the clinical development and post-marketing phases of the product lifecycle. Safety issues may affect the benefit-risk balance of the product, requiring updates to product labels and other steps that help protect patients from harm.
Signal Detection in Pharmacovigilance
Signal detection in pharmacovigilance is the systematic process of identifying and evaluating potential safety signals in the data relating to a pharmaceutical product. This process involves scrutinizing various data sources for previously unrecognized adverse events or changes in patterns of known adverse events, which might be caused by a medicine. This is vital to monitor and assure the safety of a pharmaceutical product throughout its life cycle.
Key Steps in Signal Management
-
Signal Detection: Identifying potential safety signals using various data sources such as adverse event databases, literature, and other data.
-
Signal Validation: Verifying the identified signals to ensure they are genuine and warrant further investigation.
-
Signal Confirmation: Ensuring that the identified signal is supported by robust, scientific evidence.
-
Signal Assessment: Analyzing the available data to evaluate the relationship between the medicinal product and the observed risk and providing recommendations for mitigating risk to patient safety.
-
Communication: Working with the Client to inform regulatory authorities, healthcare professionals, patients, and the public about the findings and any new safety measures or recommendations resulting from signals in the management procedure.
-
Documentation: Recording all activities, assessments, decisions, and communications for accountability and future reference.
Significance of Signal Management
-
Patient Safety: Ensures that any potential safety concerns with pharmaceutical products are identified and managed to safeguard patients.
-
Regulatory Compliance: Ensures that regulatory requirements for monitoring and ensuring product safety are met.
-
Informed Decision Making: Helps healthcare professionals and patients make informed decisions about medicinal products.
-
Risk-Benefit Balance: Ensures that the benefits of a pharmaceutical product continue to outweigh its risks during the entire lifecycle.
How ProPharma Overcomes Signal Management Challenges
-
Data Quality: Defining robust strategies to analyze available data.
-
Timely Decision Making: Ensuring that decisions and communications are made in a timely manner to protect public health.
-
Global Consistency: Globally harmonized processes to collect, process, and assess data.
News & Insights
May 19, 2026
Rethinking Biometrics Resourcing in Modern Clinical Trials
Explore how the Biometrics Functional Service Provider model transforms clinical trials, enhancing data integrity, speed, and long-term performance in a complex landscape.
May 18, 2026
The Hidden Value of Medical Information: Strengthening Brand Trust
Discover how Medical Information strengthens brand trust in the pharmaceutical industry by providing reliable, unbiased, and timely support for patients and healthcare professionals.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
December 11, 2025
ProPharma Expands Operations with New Office in Hyderabad
ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
June 2, 2026
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
May 20, 2026
Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed - Pro...
When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...
May 20, 2026
From Clinical Hold to Approval: Overcoming CMC Challenges to Achieve BLA Approva...
A critical CMC change during Phase 3 development led to a partial clinical hold, putting timelines, regulatory alignment, and commercial readiness at risk. In this case study, learn how we partnered...
May 15, 2026
Response to Regulatory Request with Subsequent Full Signal Assessment - ProPharm...
Responding to urgent regulatory safety requests requires balancing speed, scientific rigor, and global compliance. When concerns emerged regarding a potential neurotoxicity signal, the client needed...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...